Hikma Pharmaceuticals (OTCMKTS:HKMPF) Shares Gap Up – Still a Buy?

Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF) shares gapped up prior to trading on Friday. The stock had previously closed at $21.0620, but opened at $23.00. Hikma Pharmaceuticals shares last traded at $23.00, with a volume of 1,293 shares traded.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the stock. Citigroup restated a “buy” rating on shares of Hikma Pharmaceuticals in a report on Wednesday, August 12th. Barclays raised Hikma Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, September 8th. One research analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy”.

Hikma Pharmaceuticals Price Performance

The company has a 50 day simple moving average of $21.74 and a 200-day simple moving average of $20.17.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals plc is a multinational pharmaceutical company that develops, manufactures and markets a broad range of generic, branded and specialty medicines. Its portfolio includes injectable medicines, oral solid-dose products, inhalation products and other treatments used in hospitals, pharmacies and community-care settings.

The company operates through three principal businesses: Injectables, Generics and Branded Medicines. Hikma supplies injectable products to hospitals and healthcare providers, offers generic medicines primarily in the United States, and markets branded and licensed medicines across the Middle East and North Africa.